AbstractIntroduction: Diabetes Mellitus is a very commonly occurring metabolic disorder characterized by hyperglycemia and altered metabolism of lipids, proteins, and carbohydrates which is due to absolute or relative deficiency of insulin or insulin resistance. Aims and Objectives: To Study of Glimepiride versus Metformin plus Glimepiride With Respect to Glycemic Control and Lipid Profile in Type II Diabetes Mellitus Patients. Methodology: The present study was a open label hospital based prospective study undertaken to study effects of two classes of antidiabetic drugs on lipid profile and oxidative stress. The study period was October 2013 to October 2015. The study was approved by the Ethical Committee of the Medical College. The study population was carried out in all patients with both sexes of Diabetes Mellitus at Rural Hospital. A total of 60 patients with Diabetes Mellitus with Simple Random Sampling satisfying inclusion and exclusion criteria were included in the study. The patient clinically diagnosed as type 2 Diabetes Mellitus Group I (N=30): Diagnosed cases of T2DM being treated with hypoglycemic drug Glimepiride alone. Group II (N=30): Diagnosed cases of T2DM being treated with a combination of Glimepiride and Metformin. Data were double entered using Microsoft excel 2007 and analyzed using SPSS version 11. The ANOVA test where applied in the following results whenever necessary. Result: The difference between fasting blood glucose levels in Group 1 (Glimipride) and Group 2 (Metformin + Glimepiride) was statistically significant at 6 months, 12 months and 18 months i.e. p<0.05.the difference between postprandial blood glucose levels and HbA1c in Group 1 (Glimepiride) and Group 2 (Metformin + Glimipride) was statistically significant at 6 months, 12 months and 18 months i.e. p<0.05.the difference between MDA levels in Group 2 (Glimipride) and Group 4 (Metformin + Glimipride) was statistically significant at 6 months, 12 months and 18 months i.e. p<0.05. The difference between total cholesterol, triglycerides, LDL and HDL in Group 1 (Glimipride) and Group 2 (Metformin + Glimipride) was statistically significant at 6 months, 12 months and 18 months i.e. p<0.05. Conclusion: Combination treatment with metformin plus Glimepride was more effective in improving hyperglycemia, oxidative stress and lipid status in type 2 diabetics.

Keywords: Glimepiride, Metformin, Malondialdehyde level (MDA), GlycemicControl, Lipid Profile.